

Neuro-Oncology 16:vi1–vi12, 2014.
doi:10.1093/neuonc/nou249

NEURO-ONCOLOGY

BNOS 2014 Abstract submissions

P43. FSTL5 EXPRESSION IS A MARKER OF GROUP C IN METASTATIC MEDULLOBLASTOMAS

Caterina Baldi, Simone Minasi, Francesca Gianni, Felice Giangaspero, Maura Massimino, and Francesca Romana Buttarelli; Sapienza University of Rome

INTRODUCTION: Medulloblastoma (MB) is the most common malignant brain tumor in children. Four different molecular subgroups are recognized, which differ in gene expression, genomic aberrations, histology, demographics and survival: WNT and SHH groups, having specific mutations in the homonymous pathway, and groups C and D having several genetic alternations

not specific to a single pathway. The gene for follistatin-like protein 5, *FSTL5*, is overexpressed in nonSHH/nonWNT MBs poorly characterized. High-expression of *FSTL5* is significantly associated with reduced event-free and overall survival in non-WNT/non-SHH MBs. The major aim of this project is to study the *FSTL5* expression level in pediatric MBs with metastasis at the onset. **METHOD:** We investigated the protein expression of biomarkers involved in metastatic pathways by IHC and *FSTL5* expression level by RT-PCR in 26 metastatic MBs samples and correlated these data with the outcomes by Kaplan-Meier statistic analysis. **RESULTS:** 83% of Group C MBs showed high level of *FSTL5* while none of these presented down-expression. Low-expression level of *FSTL5* was found in 60% of SHH MBs and none showed over-expression. Kaplan-Meier test revealed that, in our cohort, high-expression of *FSTL5* did not correlate with worse outcome while low expression of *FSTL5* was associated with good prognosis and the co-presence of *FSTL5* with other biomarkers correlated with poorer prognosis. **CONCLUSION:** *FSTL5* is a marker of Group C in medulloblastomas with metastasis at the onset and the results highlighted decreased *FSTL5* expression as a marker of good prognosis. Group C MBs have characteristic molecular features that confirm the poorest outcome also in MBs with metastasis at the onset.